放射性医薬品市場レポート：製品タイプ、用途、最終用途、地域別、2024～2032年

世界の放射性医薬品市場規模は2023年に55億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに87億米ドルに達し、2024～2032年の間に5.1％の成長率（CAGR）を示すと予測しています。この放射性医薬品市場は、主にイメージング技術における新たな技術進歩、慢性疾患の増加、世界各国政府による有利な規制基準の導入によって牽引されています。

放射性医薬品市場分析

主要市場促進要因：放射性医薬品市場の調査レポートによると、市場は主にがんや心血管疾患などの慢性疾患の罹患率の増加が主要要因となっています。さらに、PETやSPECTを含む画像診断法の進歩は、診断の観点からこれらの放射性医薬品の使用が急増し、診断技術を変化させています。

主要市場動向：業界の動向として、同じ化合物を診断と治療に使用できるセラノスティクスへの嗜好が高まっています。さらに、放射性医薬品業界概要では、有効性を高め副作用を最小限に抑えるために、新規放射性医薬品を導入するための研究開発（R&D）への投資が行われています。

地理的動向：北米地域は、強力な医療インフラ、高額な支出、支持的な規制環境の結果、世界市場をリードしています。また、中国やインドを含むアジア太平洋の新興国は、医療費の増加と核医療の利点に関する意識の高まりにより、急速に成長すると予想されます。

競合情勢：放射性医薬品業界の主要市場参入企業には、Advanced Accelerator Applications（Novartis AG）、Bayer AG、Bracco S.p.A.、Cardinal Health Inc.、Curium Pharma、General Electric Company、IBA RadioPharma Solutions、Jubilant Pharma Limited、Lantheus Medical Imaging Inc.、Nordion Inc（Sotera Health）、NTP Radioisotopes SOC Ltd.、PharmaLogic Holdings Corp.、Siemens AGなどがあります。

課題と機会：放射性医薬品の承認プロセスには、製造プロセスの複雑さや安全性の脅威といった規制上の課題が伴う。しかし、放射性医薬品市場の予測は良好であり、市場関係者の展望は良好です。個別化医療への関心の高まりと、標的治療の一要素としての放射性医薬品の出現が市場の成長に寄与しています。研究機関との連携や製薬企業の企業間協力を通じて、市場開拓の大きな機会が提供されます。

放射性医薬品市場動向

イメージング技術の進歩

陽電子放射断層撮影法（PET）や単光子放射断層撮影法（SPECT）などの画像診断技術の進歩により、放射性医薬品の診断性が非常に高まっています。腫瘍学、神経学、循環器学などにおいて、早期治療や予防措置が必要な疾患の早期診断には、これらの技術を用いることが不可欠です。例えば、2023年の陽電子放射断層撮影（PET）の世界市場規模は約11億9,610万米ドルでした。現在、IMARC GROUPの予測によると、世界のポジトロン断層撮影（PET）市場は、2024～2032年のCAGRが5.33%で、2032年までに約19億3,000万米ドルに成長すると予測されています。IMARC GROUPの予測によると、2024～2032年までの年間平均成長率（CAGR）は5.33%で、2032年までに9億3,000万米ドルの成長が見込まれています。

慢性疾患の有病率の増加

がん、心血管疾患、神経疾患の有病率が世界的に上昇しているため、放射性医薬品に対する需要が増加していることが市場成長の原動力となっています。これらの疾患は正確な画像診断と集中的な治療が必要であり、臨床現場での放射性医薬品の利用を促しています。米国疾病対策予防センターの2020年のデータによると、米国では新たに160万3,844人ががんに罹患し、60万2,347人の命が失われました。これは、10万人当たり403人の新規がん罹患者と144人のがん関連死亡者の割合に相当します。現在、放射性医薬品はがんの早期発見・治療に必要な診断・治療用途に使用されており、市場成長を牽引しています。

良好な規制環境

この業界は、政府の動きや規制条項の影響を大きく受けています。例えば、米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制当局は、NATIONAL LIBRARY of MEDICINE（米国国立医療図書館）にあるように、新しく開発された放射性医薬品を承認するための迅速かつ効果的な手続きを提示し、技術革新と投資を奨励しています。これに加えて、医薬品クラスの迅速な仮想審査が可能であること、希少疾病用医薬品審査指定（ODD）ステータスを取得するための金銭的優遇措置があることが、多くの製薬企業が新しい放射性医薬品療法の研究開発に取り組む動機となっています。

放射性医薬品市場セグメンテーション

IMARC Groupは、市場の各セグメントにおける主要動向の分析と、2024～2032年の世界、地域、国レベルの予測を提供しています。製品タイプ別、用途別、最終用途別に市場を分類しています。

製品タイプ別内訳

診断用核医療が市場シェアの大半を占める

本レポートでは、製品タイプ別に市場を詳細に区分・分析しています。これには診断用核医療と治療用核医療が含まれます。報告書によると、診断用核医療が最大のセグメントを占めています。

診断用核医療とは、一般的に画像診断に使用される多様な放射性医薬品の投与を指します。陽電子放射断層撮影法（PET）など、さまざまなモダリティが組み込まれています。単光子放出コンピュータ断層撮影（SPECT）も同様です。がん、心臓異常、その他の神経系疾患を含む疾患の有病率の増加が観察されているため、診断用核医療市場は今後数年で拡大するものと考えられます。現在、ナーグプルの政府医科大学病院（GMCH）と超専門病院（SSH）は、核医療専門部門を立ち上げて診断能力を高める準備を進めています。この部門の提案は今年、地区計画委員会（DPC）によって9.5クローの予算で承認されました。管理的な部分が整理されたので、部門の建設はまもなく開始される予定です。

用途別内訳

腫瘍学が業界最大シェアを占める

本レポートでは、アプリケーション別の市場の詳細な区分と分析も行っています。これには腫瘍学、心臓学、神経学、内分泌学、その他が含まれます。報告書によると、腫瘍学が最大の市場シェアを占めています。

放射性医薬品の腫瘍セグメントへの応用は、標的がん治療と精密医療市場の急成長によって需要が高まっています。放射性医薬品は、PET試験やSPECT試験などによるがんの診断、病期分類、治療後の評価に欠かせないです。これはまた、IMARC GROUPが述べているように、2024～2032年にかけて6.5％の成長率（CAGR）を示し、2032年までに145億米ドルに達すると予想される放射線腫瘍学市場の拡大にも起因しています。これとは別に、腫瘍学における放射性医薬品の実現可能性と安全性を向上させるための継続的な研究開発が、このセグメントの勢いを高めると予想されています。

最終用途別内訳

診断センターが市場の主要セグメントを占める

本レポートでは、市場を最終用途別に詳細に区分・分析しています。これには、病院・クリニック、研究機関、診断センターが含まれます。報告書によると、診断センターが最大のセグメントを占めています。

診断センターが最大セグメントを占め、良好な放射性医薬品市場展望を生み出しています。様々な病態の正確な診断を達成するための核医療イメージング手技に対する需要の高まりが、診断センターの採用につながりました。診断センターでは、ポジトロン断層撮影（PET）、単光子放出コンピュータ断層撮影（SPECT）、ハイブリッドイメージングなどさまざまなイメージング技術を使用して、患者の予後を良好にします。そのため、さまざまな主要企業が先進的な診断技術を導入しており、放射性医薬品市場の価値をさらに拡大しています。例えば、2022年12月、医療イメージング技術大手であるPolarean Imaging plcは、米国食品医薬品局（FDA）がXENOVIEWを承認したと発表しました。これは、成人と12歳以上の小児患者の肺換気を評価するための磁気共鳴画像法（MRI）での使用を適応とする超偏光造影剤です。XENOVIEWは、世界で初めての吸入MRI用超偏極造影剤であり、肺医療の新時代を象徴しています。XENOVIEWは、患者に電離放射線とそれに伴うリスクを与えることなく、肺換気の新しい可視化を可能にします。XENOVIEWは、ポラリアンHPX過分極システムを通じて投与され、1回10～15秒の息止めMRI試験で使用されます。

地域別内訳

北米が市場をリードし、最大の放射性医薬品市場シェアを占める

本レポートでは、北米（米国、カナダ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、ロシア、その他）、アジア太平洋（中国、日本、インド、韓国、オーストラリア、インドネシア、その他）、ラテンアメリカ（ブラジル、メキシコ、その他）、中東アフリカの主要地域市場についても包括的に分析しています。報告書によると、北米は放射性医薬品の最大地域市場です。

北米が市場を独占しているのは、強力な医療インフラの存在、高い医療支出、技術進歩、多数の製品を提供する市場内の既存企業の存在によるものです。CENTERS FOR MEDICARE &MEDICAID SERVICESによると、米国の医療支出は2022年に4.1%増の4兆5,000億米ドルに達し、2021年の3.2%増を上回った。さらに2022年、人口の被保険者割合は92％（歴史的な高水準）に達し、民間医療保険加入者は290万人、メディケイド加入者は610万人増加しました。加えて、政府からの高い資金援助と支援、疾病の有病率の増加も市場成長の原動力となっています。したがって、このセグメントでの技術革新が促進され、効果的な新製品の採用が加速し、放射性医薬品市場の成長率が高まっています。

競合情勢

市場調査レポートでは、市場の競合情勢についても包括的な分析を行っています。主要企業の詳細プロファイルも提供しています。放射性医薬品業界の主要な市場参入企業には、Advanced Accelerator Applications（Novartis AG）、Bayer AG、Bracco S.p.A.、Cardinal Health Inc.、Curium Pharma、General Electric Company、IBA RadioPharma Solutions、Jubilant Pharma Limited、Lantheus Medical Imaging Inc.、Nordion Inc.（Sotera Health）、NTP Radioisotopes SOC Ltd.、PharmaLogic Holdings Corp.、Siemens AGなどがあります。

（これは主要参入企業の一部であり、完全なリストは報告書に記載されていることに留意されたい）。

現在、放射性医薬品市場の主要企業は、市場での地位と足場を維持するために様々な戦略的取り組みを行っています。これらの取り組みには、効率性と安全性を高めた新しい放射性医薬品を開発・革新するための研究開発投資が含まれます。研究開発、技術革新に加えて、各社は製品パイプラインや販売網を拡大するための戦略的提携やパートナーシップにも取り組んでいます。例えば、2023年11月、ウィスコンシン州を拠点とする核融合技術企業であるSHINE Technologiesは、最近、Nucleus RadioPharmaとルテチウム177を供給する長期供給契約を締結しました。放射性同位元素は、神経内分泌腫瘍、前立腺がん、その他の固形がんを対象に開発中のものを含め、がん治療で利用されています。神経内分泌腫瘍や前立腺がんに特化した放射性医薬品治療を対象とするNucleus RadioPharmaの放射性医薬品治療（RLT）をサポートするため、シャインは数年間、Lu-177を供給します。また、一部の主要企業は、今後予定されている規制基準や既存の規制基準に沿って、放射性医薬品の需要増に対応するための製造プロセスの強化や最適化に取り組んでいます。

放射性医薬品市場ニュース

2023年3月、国際原子力機関（IAEA）は、日本の11の大学や機関と連携し、アジア太平洋のがん医療サービスの強化を目指す「Rays of Hope」パートナーシップを開始します。

2024年2月、Bristol Myers SquibbがRayzeBioの買収を完了し、アクチニウムをベースとした放射性医薬品プラットフォームでポートフォリオを強化。この買収により、固形がん患者の治療法として最も急成長している放射性医薬品治療（RPT）が導入されます。

本レポートで扱う主要質問

• 2023年における放射性医薬品市場の世界市場規模は？
• 2024～2032年における放射性医薬品市場の世界市場成長率は？
• 世界の放射性医薬品市場に対するCOVID-19の影響は？
• 世界の放射性医薬品市場を牽引する主要要因は何か
• 放射性医薬品市場の世界における製品タイプ別内訳は？
• 世界の放射性医薬品市場の用途別内訳は？
• 放射性医薬品市場の用途別内訳は？
• 放射性医薬品市場の世界における主要地域は？
• 放射性医薬品市場の世界における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界の放射性医薬品市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：製品タイプ別

• 核医療診断
• 核医療治療

第7章 市場内訳：用途別

• 腫瘍学
• 心臓病学
• 神経学
• 内分泌学
• その他

第8章 市場内訳：最終用途別

• 病院とクリニック
• 研究機関
• 診断センター

第9章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場動向
  • 市場内訳：国別
  • 市場予測

第10章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第13章 価格分析

第14章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Advanced Accelerator Applications（Novartis AG）
  • Bayer AG
  • Bracco S.p.A.
  • Cardinal Health Inc.
  • Curium Pharma
  • General Electric Company
  • IBA RadioPharma Solutions
  • Jubilant Pharma Limited
  • Lantheus Medical Imaging Inc
  • Nordion Inc.（Sotera Health）
  • NTP Radioisotopes SOC Ltd
  • PharmaLogic Holdings Corp.
  • Siemens AG

List of Figures

• Figure 1: Global: Radiopharmaceuticals Market: Major Drivers and Challenges
• Figure 2: Global: Radiopharmaceuticals Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: Radiopharmaceuticals Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 4: Global: Radiopharmaceuticals Market: Breakup by Product Type (in %), 2023
• Figure 5: Global: Radiopharmaceuticals Market: Breakup by Application (in %), 2023
• Figure 6: Global: Radiopharmaceuticals Market: Breakup by End Use (in %), 2023
• Figure 7: Global: Radiopharmaceuticals Market: Breakup by Region (in %), 2023
• Figure 8: Global: Radiopharmaceuticals (Diagnostic Nuclear Medicine) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 9: Global: Radiopharmaceuticals (Diagnostic Nuclear Medicine) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 10: Global: Radiopharmaceuticals (Therapeutic Nuclear Medicine) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 11: Global: Radiopharmaceuticals (Therapeutic Nuclear Medicine) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 12: Global: Radiopharmaceuticals (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 13: Global: Radiopharmaceuticals (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 14: Global: Radiopharmaceuticals (Cardiology) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 15: Global: Radiopharmaceuticals (Cardiology) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 16: Global: Radiopharmaceuticals (Neurology) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 17: Global: Radiopharmaceuticals (Neurology) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 18: Global: Radiopharmaceuticals (Endocrinology) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 19: Global: Radiopharmaceuticals (Endocrinology) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 20: Global: Radiopharmaceuticals (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 21: Global: Radiopharmaceuticals (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 22: Global: Radiopharmaceuticals (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 23: Global: Radiopharmaceuticals (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 24: Global: Radiopharmaceuticals (Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 25: Global: Radiopharmaceuticals (Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 26: Global: Radiopharmaceuticals (Diagnostic Centers) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 27: Global: Radiopharmaceuticals (Diagnostic Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 28: North America: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 29: North America: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 30: United States: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 31: United States: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 32: Canada: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 33: Canada: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 34: Asia-Pacific: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 35: Asia-Pacific: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 36: China: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 37: China: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 38: Japan: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 39: Japan: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 40: India: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 41: India: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 42: South Korea: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 43: South Korea: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 44: Australia: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 45: Australia: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 46: Indonesia: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 47: Indonesia: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 48: Others: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 49: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 50: Europe: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 51: Europe: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 52: Germany: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 53: Germany: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 54: France: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 55: France: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 56: United Kingdom: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 57: United Kingdom: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 58: Italy: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 59: Italy: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 60: Spain: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 61: Spain: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 62: Russia: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 63: Russia: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 64: Others: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 65: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 66: Latin America: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 67: Latin America: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 68: Brazil: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 69: Brazil: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 70: Mexico: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 71: Mexico: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 72: Others: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 73: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 74: Middle East and Africa: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
• Figure 75: Middle East and Africa: Radiopharmaceuticals Market: Breakup by Country (in %), 2023
• Figure 76: Middle East and Africa: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 77: Global: Radiopharmaceuticals Industry: SWOT Analysis
• Figure 78: Global: Radiopharmaceuticals Industry: Value Chain Analysis
• Figure 79: Global: Radiopharmaceuticals Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Radiopharmaceuticals Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Radiopharmaceuticals Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
• Table 3: Global: Radiopharmaceuticals Market Forecast: Breakup by Application (in Million US$), 2024-2032
• Table 4: Global: Radiopharmaceuticals Market Forecast: Breakup by End Use (in Million US$), 2024-2032
• Table 5: Global: Radiopharmaceuticals Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 6: Global: Radiopharmaceuticals Market: Competitive Structure
• Table 7: Global: Radiopharmaceuticals Market: Key Players

The global radiopharmaceuticals market size reached US$ 5.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032. The radiopharmaceuticals market is primarily driven by the emerging technological advancements in imaging technology, the increasing incidences of chronic ailments, and the implementation of favorable regulatory standards by the government across the globe.

Radiopharmaceuticals Market Analysis:

Major Market Drivers: As per the radiopharmaceuticals market research report, the market is predominantly driven by the growing incidence of chronic diseases, mainly cancer and cardiovascular disorders. Additionally, advances in imaging procedures including PET and SPECT alter the diagnosis skill with the surging use of these radiopharmaceuticals for diagnostic perspectives.

Key Market Trends: The trend that is taking shape in the industry is the growing preference for theranostics, where the same compound can be used for diagnosis and therapy. Furthermore, the radiopharmaceuticals industry overview shows investments in research and development (R&D) to introduce novel radiopharmaceuticals to inflate efficacy and minimize side effects.

Geographical Trends: The North America region leads the global market as a result of the strong healthcare infrastructure, high expenditure, and supportive regulatory environment. It is also expected that emerging economies in Asia-Pacific including China and India will grow rapidly due to the increase in health expenditure and awareness concerning the benefits of nuclear medicine.

Competitive Landscape: Some of the major market players in the radiopharmaceuticals industry include Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp. and Siemens AG, among many others.

Challenges and Opportunities: The radiopharmaceutical approval process is associated with regulatory challenges, such as the complexity of manufacturing processes and safety threats. However, the radiopharmaceuticals market forecast is favorable and market players have good prospects. The growing interest in personalized medicine and the emergence of radiopharmaceuticals as a component of targeted therapy contribute to the market growth. It offers vast opportunities for market development through collaboration with research institutes and intercompany cooperation for pharmaceutical enterprises.

Radiopharmaceuticals Market Trends:

Technological Advancements in Imaging Technologies:

The advancements in imaging technologies, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), have highly enhanced the diagnostic nature of radiopharmaceuticals. It is vital in the early diagnosis of conditions that require early treatment or preventive measures in oncology, neurology, and cardiology, using these technologies. For instance, in 2023, the global market for positron emission tomography (PET) was valued at approximately $1.196.1 Million. Presently, the global positron emission tomography (PET) market is projected to grow to about $1.93 billion by 2032, with a compound annual growth rate (CAGR) of 5.33% from 2024 through 2032, according to forecasts by the IMARC GROUP. The growth is attributed to advances in imaging technology and the implementation of these advanced systems in medical diagnostics across the world.

Increasing Prevalence of Chronic Diseases:

The market growth is driven by the increasing demand for radiopharmaceuticals due to the rising prevalence of cancer, cardiovascular diseases, and neurological disorders worldwide. These diseases necessitate accurate diagnostic imaging and focused therapeutics, prompting the utilization of radiopharmaceuticals in clinical practice. According to CENTERS for DISEASE CONTROL AND PREVENTION data in 2020, the United States witnessed the reporting of 1,603,844 new incidences of cancer and the unfortunate loss of 602,347 lives due to the disease. This equates to a rate of 403 new cancer cases and 144 cancer-related deaths per 100,000 individuals. Currently, radiopharmaceuticals are used in diagnostic and treatment applications necessary for the early detection and treatment of cancers, thus driving market growth.

Favorable Regulatory Environment:

The industry is significantly impacted by governmental actions and regulatory provisions. For instance, regulatory authorities such as the U.S. FOOD AND DRUG ADMINISTRATION (FDA) and the EUROPEAN MEDICINES AGENCY (EMA) present instant and effective procedures to approve newly developed radiopharmaceuticals encouraging innovation and investment as per the NATIONAL LIBRARY of MEDICINE. Besides this, the possibility of a rapid virtual review of drug classes, along with financial incentives for obtaining Orphan Drug Designation (ODD) status, motivates many pharmaceutical companies to engage in research and development (R&D) of new radiopharmaceutical therapies.

Radiopharmaceuticals Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product type, application, and end use.

Breakup by Product Type:

Diagnostic Nuclear Medicine

Therapeutic Nuclear Medicine

Diagnostic nuclear medicine accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product type. This includes diagnostic nuclear medicine and therapeutic nuclear medicine. According to the report, diagnostic nuclear medicine represented the largest segment.

Diagnostic nuclear medicine refers to the administration of a diverse number of radiopharmaceuticals typically used for imaging. It incorporates different modalities such as positron emission tomography (PET). The same also applies to single-photon emission computed tomography (SPECT). Due to the observed increase in the prevalence of diseases including cancer, cardiac abnormalities, and other neuronal conditions, the diagnostic nuclear medicine market is bound to expand in the coming years. At present, the Government Medical College and Hospital (GMCH) and the Super Speciality Hospital (SSH) in Nagpur are preparing to elevate their diagnostic capabilities by launching a dedicated nuclear medicine department. The proposal for this department was approved by the District Planning Committee (DPC) this year with a 9.5 crore budget. Since the administrative part has been sorted, the construction of the department is to be initiated soon.

Breakup by Application:

Oncology

Cardiology

Neurology

Endocrinology

Others

Oncology holds the largest share of the industry

A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes oncology, cardiology, neurology, endocrinology, and others. According to the report, oncology accounted for the largest market share.

Oncology applications in radiopharmaceuticals are experiencing rising demand, facilitated by the rapid growth of the targeted cancer therapies and precision medicine market. Radiopharmaceuticals are crucial in the diagnosis, staging, and post-treatment evaluation of cancers through PET and SPECT scans, among other modalities. This is also attributed to the expanding radiation oncology market which is expected to reach US$ 14.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.5% during 2024-2032 as stated by IMARC GROUP. Apart from this, ongoing research and development efforts to improve the feasibility and safety of radiopharmaceuticals in oncology are anticipated to boost the momentum of the sector.

Breakup by End Use:

Hospitals and Clinics

Research Institutes

Diagnostic Centers

Diagnostic centers represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the end use. This includes hospitals and clinics, research institutes, and diagnostic centers. According to the report, diagnostic centers represented the largest segment.

Diagnostic centers represent the largest segment and are creating a favorable radiopharmaceuticals market outlook. The rising demand for nuclear imaging procedures to achieve an accurate diagnosis of various medical conditions resulted in the adoption of diagnostic centers. It uses various imaging techniques such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and hybrid imaging to ensure a favorable patient outcome. Hence various key players are introducing advanced diagnostic technologies which is further expanding the radiopharmaceuticals market value. For instance, in December 2022, Polarean Imaging plc, a leading medical imaging technology company, announced that the U.S. Food and Drug Administration (FDA) approved XENOVIEW. It is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) to assess lung ventilation in adults and pediatric patients 12 years of age and older. XENOVIEW represents a new era of pulmonary medicine since it is the very first inhaled MRI hyperpolarized contrast agent. It makes it possible to obtain a novel visualization of lung ventilation without exposing the patient to ionizing radiation and its associated risks. It is administered via the Polarean HPX hyperpolarization system, XENOVIEW is dispensed in a single 10-15 second breath hold MRI practice.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest radiopharmaceuticals market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for radiopharmaceuticals.

North America is dominating the market due to the presence of strong healthcare infrastructure, high healthcare spending, technological advancements, and the presence of established players within the market with numerous product offerings. According to the CENTERS FOR MEDICARE & MEDICAID SERVICES, United States health care spending grew 4.1% to reach $4.5 trillion in 2022, faster than the increase of 3.2% in 2021. Moreover, in 2022, the insured share of the population reached 92% (a historic high) and private health insurance enrollment increased by 2.9 million individuals and Medicaid enrollment increased by 6.1 million individuals. In addition, high government funding and support, as well as an increasing prevalence of disease, are also driving the market growth. Hence, this promotes innovation within the sector and accelerates the introduction of new and effective products generating an increasing radiopharmaceuticals market growth rate.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the radiopharmaceuticals industry include Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp. and Siemens AG.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Currently, key players in the radiopharmaceuticals market are involved in various strategic initiatives to sustain their market positions and footholds. These initiatives include research and development investments to develop and innovate new radiopharmaceutical products with enhanced efficacies and safety. In addition to research, development, and innovation, the companies are also involved in strategic collaborations and partnerships to expand their product pipeline and distribution networks. For instance, in November 2023, SHINE Technologies, a fusion technology company based in Wisconsin, has recently entered a long-term supply agreement with Nucleus RadioPharma to supply lutetium-177. A radioisotope is utilized in cancer treatment therapies, including those under development for neuroendocrine tumors, prostate cancer, and other solid tumors. For several years, SHINE will supply Lu-177 to support Nucleus RadioPharma's radioligand therapy (RLT) offerings, which target radiopharmaceutical treatments specifically designed for neuroendocrine tumors and prostate cancer. Some key players are also involved in enhancing and optimizing manufacturing production processes to meet the growing demand for radiopharmaceuticals in line with upcoming and existing regulatory standards.

Radiopharmaceuticals Market News:

March 2023: The INTERNATIONAL ATOMIC ENERGY AGENCY (IAEA) initiates the Rays of Hope partnership in collaboration with 11 Japanese universities and institutions which aims to bolster cancer care services across Asia and the Pacific region.

February 2024: Bristol Myers Squibb finalized the acquisition of RayzeBio, enhancing its portfolio with a distinctive actinium-based radiopharmaceutical platform. This addition also introduces radiopharmaceutical therapeutics (RPTs), which are emerging as one of the most rapidly growing treatment modalities for addressing solid tumors in patients.

Key Questions Answered in This Report

• 1. What was the size of the global radiopharmaceuticals market in 2023?
• 2. What is the expected growth rate of the global radiopharmaceuticals market during 2024-2032?
• 3. What has been the impact of COVID-19 on the global radiopharmaceuticals market?
• 4. What are the key factors driving the global radiopharmaceuticals market?
• 5. What is the breakup of the global radiopharmaceuticals market based on the product type?
• 6. What is the breakup of the global radiopharmaceuticals market based on the application?
• 7. What is the breakup of the global radiopharmaceuticals market based on the end use?
• 8. What are the key regions in the global radiopharmaceuticals market?
• 9. Who are the key players/companies in the global radiopharmaceuticals market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Radiopharmaceuticals Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Diagnostic Nuclear Medicine
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Therapeutic Nuclear Medicine
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Application

• 7.1 Oncology
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Cardiology
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Neurology
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Endocrinology
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End Use

• 8.1 Hospitals and Clinics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Research Institutes
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Diagnostic Centers
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Advanced Accelerator Applications (Novartis AG)
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Bayer AG
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Bracco S.p.A.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 SWOT Analysis
  • 14.3.4 Cardinal Health Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Curium Pharma
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 General Electric Company
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 IBA RadioPharma Solutions
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Jubilant Pharma Limited
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Lantheus Medical Imaging Inc
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 Nordion Inc. (Sotera Health)
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 SWOT Analysis
  • 14.3.11 NTP Radioisotopes SOC Ltd
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
  • 14.3.12 PharmaLogic Holdings Corp.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
  • 14.3.13 Siemens AG
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio
    • 14.3.13.3 Financials
    • 14.3.13.4 SWOT Analysis